ClinicalTrials.gg

Program

MK-7602

Its studies are mostly in Malaria, led by Merck.

Furthest: phase 1, since Feb 28, 20243 company-led studies, 1 open or runningNext primary completion: Apr 5, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck31 open or runningphase 1since Feb 28, 2024Feb 28, 2024Apr 5, 2027phase 1 · NCT07919028

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 28, 2024First study: phase 1 study in MalariaFirst studyNCT06294912 · 16 enrolled · Australia
  2. Jan 21, 2025Phase 1 study in HealthyNCT06797674 · 34 enrolled · United States
  3. Oct 30, 2026Phase 1 study in HealthyNCT07919028 · 24 planned

Ahead

  1. Apr 5, 2027Primary completion: phase 1 study in HealthyNCT07919028

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07919028Healthy1Not yet recruitingApr 5, 202724
NCT06797674Healthy · United States1CompletedAug 12, 202534
NCT06294912Malaria · Australia1CompletedJan 6, 202516

How it is read

Names in the registry

  • “MK-7602”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.